Shanghai Fosun Pharmaceutical (Group) Co (HKSE:02196) Debt-to-Revenue : 0.96 (As of Mar. 2025)

View and export this data going back to 2012. Start your Free Trial

What is Shanghai Fosun Pharmaceutical (Group) Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Shanghai Fosun Pharmaceutical (Group) Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was HK$23,652 Mil. Shanghai Fosun Pharmaceutical (Group) Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was HK$15,215 Mil. Shanghai Fosun Pharmaceutical (Group) Co's annualized Revenue for the quarter that ended in Mar. 2025 was HK$40,402 Mil. Shanghai Fosun Pharmaceutical (Group) Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2025 was 0.96.

Shanghai Fosun Pharmaceutical (Group) Co Debt-to-Revenue Historical Data

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fosun Pharmaceutical (Group) Co Debt-to-Revenue Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Revenue

Get a 7-Day Free Trial

0.79

0.62

0.69

0.85

0.88

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Debt-to-Revenue	Get a 7-Day Free Trial															0.86	0.84	0.83	0.89	0.96

Competitive Comparison of Shanghai Fosun Pharmaceutical (Group) Co's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Fosun Pharmaceutical (Group) Co's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Fosun Pharmaceutical (Group) Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Shanghai Fosun Pharmaceutical (Group) Co's Debt-to-Revenue falls into.

Save Embed

;

Save Embed

;

Shanghai Fosun Pharmaceutical (Group) Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Shanghai Fosun Pharmaceutical (Group) Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(24740.778	+	13864.221)	/	43846.298
	=	0.88

Shanghai Fosun Pharmaceutical (Group) Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2025 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(23651.798	+	15214.62)	/	40402.404
	=	0.96

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2025) Revenue data.

Shanghai Fosun Pharmaceutical (Group) Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Shanghai Fosun Pharmaceutical (Group) Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Fosun Pharmaceutical (Group) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fosun Pharmaceutical (Group) Co Ltd (HKSE:02196) » Definitions » Debt-to-Revenue

Traded in Other Exchanges

SFOSF:USA 08HH:Germany 600196:China

Address

No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233

Website

https://www.fosunpharma.com

Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.

Executives

Blackrock, Inc.	2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.
Shanghai Fosun High Technology (group) Co., Ltd.
Fosun International Holdings Ltd.	2201 Interest of corporation controlled by you
Fosun International Limited	2101 Beneficial owner
Guo Guangchang	2201 Interest of corporation controlled by you

Shanghai Fosun Pharmaceutical (Group) Co Headlines

No Headlines